Amylyx Pharmaceuticals, Inc.
AMLX
Classement en actions
#4526
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Prix de l'action
$27.22
Capitalisation boursière
$3.42B
Changement (1 jour)
3.32%
Changement (1 an)
82.04%
Pays
US
Échange Amylyx Pharmaceuticals, Inc. (AMLX)
Catégorie
Healthcare
EPS pour Amylyx Pharmaceuticals, Inc. (AMLX)
EPS au June 2026 TTM : $-1.41
Selon les derniers rapports financiers et le cours de l'action de Amylyx Pharmaceuticals, Inc., l’EPS actuel de la société (TTM) est de $-1.41. À la fin de 2023, la société avait un EPS de $0.73 une augmentation par rapport à celui de 2022, qui était de $-2.98.
Historique de l'EPS de Amylyx Pharmaceuticals, Inc. de 2019 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
